ArticleCancer discovery2019
Cells Lacking the
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 124 papers.
0numbers the graph read from it
0cells of the map it votes in
124citing papers in PubMed
8.0field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
124 citing papers in PubMed, 174 citations in OpenAlex.
- Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.Cancer discovery · 2020Trial
- Exceptional treatment responses and molecular markers among 103 colorectal cancer cell lines.Molecular biomedicine · 2026Article
- miR-640 Enhances Abemaciclib Sensitivity by Suppressing CDK Inhibitor Resistance-Associated Genes in Breast Cancer Cells.Journal of cellular and molecular medicine · 2026Article
- Dual Inhibition of TRIP13 and Aurora A Induces Mitotic DNA Damage and Concurrent Pyroptotic-Apoptotic Cell Death in Rb-Deficient Cancer Cells.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancer.British journal of cancer · 2026Article
- Emerging Strategies to Inhibit the G1/S Transition for Cancer Therapy.Cancer research · 2026Review
- Tyrosine phosphoproteome profiling identifies cell-intrinsic signals limiting the efficacy of tyrosine kinase inhibitor therapies.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Mitotic Machinery Dysregulation in Lung Cancer: Biological Roles, Therapeutic Targeting, and Combination Strategies.Pharmaceutics · 2026Review
- Tumour specific HORMAD1 expression perturbs mitotic arrest and drives sensitivity to mitotic kinase inhibitors.Nature communications · 2026Article
- RB1 inactivation in cutaneous carcinomas.Histopathology · 2026Review
- RB1-I680T mutation potentiates tumor growth and chemotherapy sensitivity in non-small cell lung cancer via derepressing E2F1 transcription.Cell communication and signaling : CCS · 2026Article
- The Five-Decade Journey of Small Cell Lung Cancer.Cancer communications (London, England) · 2026Review
- Discovery of the first-in-class Aurora B kinase selective degrader.European journal of medicinal chemistry · 2025Article
- Article
- Article
- Molecular mechanisms and clinical insights in transformed small cell lung cancer: a narrative review.Translational lung cancer research · 2025Review
- BaCoN (Balanced Correlation Network) improves prediction of gene buffering.Molecular systems biology · 2025Article
- Myc family proteins: Molecular drivers of tumorigenesis and resistance in neuroendocrine tumors.Biochimica et biophysica acta. Reviews on cancer · 2025Review
- Aurora kinases signaling in cancer: from molecular perception to targeted therapies.Molecular cancer · 2025Review
64 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
29 authors at 11 institutions in 6 countries.
Matthew G OserDepartment of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Raquel FonsecaDepartment of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Abhishek A ChakrabortyDepartment of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Rachel BroughThe CRUK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom.
Alexander SpektorHoward Hughes Medical Institute, Chevy Chase, Maryland.
Rebecca B JenningsDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Abdallah FlaifelDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-6705-018X
Jesse S NovakDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Aditi GulatiThe CRUK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom.
Elizabeth BussDepartment of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Scott T YoungerBroad Institute of Harvard and MIT, Cambridge, Massachusetts.
Samuel K McBrayerDepartment of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Glenn S CowleyBroad Institute of Harvard and MIT, Cambridge, Massachusetts.
Dennis M BonalLurie Family Imaging Center, Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Quang-De NguyenLurie Family Imaging Center, Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Laura Brulle-SoumareXenTech, Genopole, France.
Paula TaylorIMED Oncology, AstraZeneca, Cheshire, United Kingdom.
Stefano CairoXenTech, Genopole, France.
Colm J RyanSystems Biology Ireland, University College Dublin, Dublin, Republic of Ireland.ORCID 0000-0003-2750-9854
Elizabeth J PeaseIMED Discovery Sciences, AstraZeneca, Cambridge, United Kingdom.
Kim MarateaIMED Drug Safety and Metabolism, AstraZeneca, Boston, Massachusetts.
Jon TraversIMED Oncology, AstraZeneca, Cheshire, United Kingdom.
David E RootBroad Institute of Harvard and MIT, Cambridge, Massachusetts.ORCID 0000-0001-5122-861X
Sabina SignorettiDepartment of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
David PellmanHoward Hughes Medical Institute, Chevy Chase, Maryland.
Susan AshtonIMED Oncology, AstraZeneca, Cheshire, United Kingdom.
Christopher J LordThe CRUK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom.
Simon T BarryIMED Oncology, AstraZeneca, Cambridge, United Kingdom.
William G KaelinDepartment of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. William_Kaelin@dfci.harvard.edu.
Brigham and Women's Hospital · USAstraZeneca (United Kingdom) · GBBroad Institute · USBreast Cancer Now · GBHoward Hughes Medical Institute · USDana-Farber Brigham Cancer Center · USDana-Farber Cancer Institute · USGenopole (France) · FRAstraZeneca (France) · FRAstraZeneca (United States) · USUniversity College Dublin · IE
Funding
VectorP30CA006516 · NCI · DANA-FARBER CANCER INSTITUTE · PI JENNIFER W MACK · 1985 to 2026
$330.6MTreating the P13-Kinase/AKTP50CA101942 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI David McDermott · 2003 to 2026
$53.4MTargeting the Vasular SystemP50CA165962 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI WENDY Beth LONDON · 2013 to 2026
$33.5MPhysician Scientist Training in Cancer ResearchT32CA009172 · NCI · DANA-FARBER CANCER INSTITUTE · PI Jennifer R Brown, James A. DeCaprio · 1985 to 2026
$17.1MThe von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer: Insights into Oxygen Sensing and Treating Cancers Caused by Undruggable MutationsR35CA210068 · NCI · DANA-FARBER CANCER INST · PI WILLIAM G. KAELIN · 2016 to 2026
$10.8MThe RBP2/JARID1A/KDM5A Histone Demethylase as a Potential Drug Target in CancerR01CA076120 · NCI · DANA-FARBER CANCER INSTITUTE · PI KAELIN, WILLIAM G. · 1998 to 2015
$3.6MPolyploidy, Aneuploidy and Genome StabilityR01CA213404 · NCI · DANA-FARBER CANCER INST · PI PELLMAN, DAVID S · 2017 to 2024
$3.5MNew Therapeutic Targets in Small Cell Lung Cancer that are Epistatic or Synthetic Lethal with pRB LossK08CA222657 · NCI · DANA-FARBER CANCER INST · PI OSER, MATTHEW GILBERT · 2017 to 2021
$886kThe mechanism of DNA damage and chromothripsis from chromosome segregation errorsK08CA208008 · NCI · DANA-FARBER CANCER INST · PI SPEKTOR, ALEXANDER · 2016 to 2020
$886kCancer Research UK 14276Cancer Research UK 24439Howard Hughes Medical InstituteNCI NIH HHS K08 CA208008NCI NIH HHS K08 CA222657NCI NIH HHS P30 CA006516NCI NIH HHS P50 CA101942NCI NIH HHS P50 CA165962NCI NIH HHS R01 CA076120NCI NIH HHS R01 CA213404NCI NIH HHS R35 CA210068NCI NIH HHS T32 CA009172Wellcome Trust
Abstract
Small cell lung cancer (SCLC) accounts for 15% of lung cancers and is almost always linked to inactivating
Indexed as
Cell ProliferationGenes, Tumor SuppressorMutationAnimalsAntineoplastic AgentsApoptosisAurora Kinase BChromosome SegregationCRISPR-Cas SystemsDrug Resistance, NeoplasmFemaleHumansLung NeoplasmsMiceMice, NudeRetinoblastoma Binding ProteinsAntineoplastic AgentsAURKB protein, humanAurora Kinase BRB1 protein, humanRetinoblastoma Binding ProteinsUbiquitin-Protein Ligases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.